Endobiogeny: A global approach to systems biology (Part 1 of 2)

Global Advances In Health and Medicine

Volumn 2, Issue 1, 2013, Pages 64-78

  Lapraz, Jean Claude ^a   Hedayat, Kamyar M ^b  

^a Institut d'Histoire de la Médecine   (France)

^b Integrative physiology   (United States)

Author keywords

Endobiogeny; Endocrinology; Functional medicine; Reductionism; Systems biology

Indexed keywords

BIOLOGICAL MARKER;

ADRENERGIC SYSTEM; BIOINFORMATICS; BLOOD TEST; CHOLINERGIC SYSTEM; CLINICAL MEDICINE; DIAGNOSTIC TEST; DISEASE MODEL; ENDOBIOGENY; ENDOCRINE SYSTEM; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; INFORMATION; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SYSTEMS BIOLOGY;

EID: 84903588529     PISSN: 2164957X     EISSN: 21649561     Source Type: Journal    
DOI: 10.7453/gahmj.2013.2.1.011     Document Type: Review

References (217)

1. Strange K. The end of "naive reductionism": rise of systems biology or renaissance of physiology? Am J Physiol Cell Physiol. 2005;288(5):C968-74.
2. Lyons AS, Petrucelli R. Medicine: An illustrated history. New York: Harry N. Abrams; 1987.
3. Fang FC, Casadevall A. reductionistic and holistic science. Infect Immun. 2011;79(4):1401-4.
4. Hanin L. Why victory in the war on cancer remains elusive: biomedical hypotheses and mathematical models. Cancers. 2011;3:340-67.
5. Jackson Nakazawa D. The autoimmune epidemic: bodies gone haywire in a world out of balance-and the cutting-edge science that promises hope. 1st ed. New York: Touchstone; 2008.
6. Laplace P-S. Essai philosophique sur les probabilités, p.4: éd. Bachelier; 1840.
7. Descartes R. Discours de la méthode: pour bien conduire sa raison, et chercher la vérité dans les sciences (A discourse of the method for conducting oneself with reason, and searching for truth in the sciences), Vol Cinquième: éd. Cousin; 1637:142.
8. Verduijn M, Jager KJ, Zoccali C, Dekker FW. Genetic association studies: discovery of the genetic basis of renal disease. Nephron Clin Pract. 2011;119(3):c236-9.
9. Woods MO, Younghusband HB, Parfrey PS, et al. The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. Gut. Oct 2010;59(10):1369-77.
10. Moller CC, Pollak MR, Reiser J. The genetic basis of human glomerular disease. Adv Chronic Kidney Dis. 2006;13(2):166-73.
11. Day IN, Gu D, Ganderton RH, Spanakis E, Ye S. Epidemiology and the genetic basis of disease. Int J Epidemiol. 2001;30(4):661-7.
12. Partridge M. Oral cancer: 1. The genetic basis of the disease. Dent Update. 2000;27(5):242-8.
13. Tsipouras P, Silverman DI. The genetic basis of aortic disease. Marfan syndrome and beyond. Cardiol Clin. 1999;17(4):683-96.
14. Tay A. Genetic basis of disease: studies of eicosanoids and some complex disease traits. Clin Sci (Lond). 1996;91(3):264-6.
15. Johnson MC, Payne RM, Grant JW, Strauss AW. The genetic basis of paediatric heart disease. Ann Med. Jun 1995;27(3):289-300.
16. Arnold A. Genetic basis of endocrine disease 5. Molecular genetics of parathyroid gland neoplasia. J Clin Endocrinol Metab. Nov 1993;77(5):1108-12.
17. McPhaul MJ, Marcelli M, Zoppi S, Griffin JE, Wilson JD. Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance. J Clin Endocrinol Metab. Jan 1993;76(1):17-23.
18. Fagin JA. Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasia. J Clin Endocrinol Metab. Dec 1992;75(6):1398-1400.
19. Wadia RS. Another genetic basis for vascular disease. Natl Med J India. 1992;5(2):71-2.
20. White PC, New MI. Genetic basis of endocrine disease 2: congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1992;74(1):6-11.
21. Taylor SI, Cama A, Accili D, et al. Genetic basis of endocrine disease. 1. Molecular genetics of insulin resistant diabetes mellitus. J Clin Endocrinol Metab. 1991;73(6):1158-63.
22. Grant DA. Genetic polymorphism of the alcohol metabolising enzymes as a basis for alcoholic liver disease. Br J Addict. 1988;83(11):1255-9.
23. Kidson C, Chen P. DNA damage, DNA repair and the genetic basis of Alzheimer's disease. Prog Brain Res. 1986;70:291-301.
24. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595-638.
25. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics-a review in human disease diagnosis. Anal Chim Acta. 2010;659(1-2):23-33.
26. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009;15(2):431-40.
27. Wang H, Tso VK, Slupsky CM, Fedorak RN. Metabolomics and detection of colorectal cancer in humans: a systematic review. Future Oncol. 2010;6(9):1395-406.
28. Heazell AE, Brown M, Worton SA, Dunn WB. Review: The effects of oxygen on normal and pre-eclamptic placental tissue-insights from metabolomics. Placenta. 2011;32 Suppl 2:S119-24.
29. Galvao ER, Martins LM, Ibiapina JO, Andrade HM, Monte SJ. Breast cancer proteomics: a review for clinicians. J Cancer Res Clin Oncol. 2011;137(6):915-25.
30. Buczynski MW, Dumlao DS, Dennis EA. Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res. 2009;50(6):1015-38.
31. Schiffer E, Mischak H, Zimmerli LU. Proteomics in gerontology: current applications and future aspects-a mini-review. Gerontology. 2009;55(2):123-37.
32. Gast MC, Schellens JH, Beijnen JH. Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat. 2009;116(1):17-29.
33. Conrad DH, Goyette J, Thomas PS. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med. 2008;23 Suppl 1:78-84.
34. Drake TA, Ping P. Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Proteomics approaches to the systems biology of cardiovascular diseases. J Lipid Res. 2007;48(1):1-8.
35. Rice GE, Georgiou HM, Ahmed N, Shi G, Kruppa G. Translational proteomics: developing a predictive capacity-a review. Placenta. 2006;27 Suppl A:S76-86.
36. Patel PS, Telang SD, Rawal RM, Shah MH. A review of proteomics in cancer research. Asian Pac J Cancer Prev. Apr-Jun 2005;6(2):113-117.
37. Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet. 2001;2:343-72.
38. Hood L, Rowen L, Galas DJ, Aitchison JD. Systems biology at the Institute for Systems Biology. Briefings in functional genomics and proteomics. 2008;7(4):239-248.
39. Von Bertalanffy L. The history and status of general systems theory. Acad Manage J. 1972;15(4):407-26.
40. Miller JG. Living systems. New York: McGraw-Hill; 1978.
41. Red'ko VG, Prokhorov DV, Burtsev MB. Theory of functional systems, adaptive critics and neural networks. Paper presented at: Proceedings of International Joint Conference on Neural Networks, 2004; Budapest.
42. Miller JG. Toward a general theory for the behavioral sciences. Am Psychol. 1955;10(9):513-531.
43. Capra F. The web of life: a new scientific understanding of living systems. 1st Anchor Books ed. New York: Anchor Books; 1996.
44. Tubbs S. A systems approach to small group interaction. 11th ed. New York: McGraw-Hill Humanities/Social Sciences/Languages; 2011.
45. Clayton T, Radcliff N. Sustainability: a systems approach. 1st ed: London: Routledge; 1996.
46. Capra F, Pauli GA. Steering business toward sustainability. Tokyo; New York: United Nations University Press; 1995.
47. Dryden GW, Jr., Deaciuc I, Arteel G, McClain CJ. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep. 2005;7(4):308-16.
48. James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J. 2009;23(8):2374-83.
49. Lee DH, Gross MD, Steffes MW, Jacobs DR Jr. Is serum gamma-glutamyltransferase a biomarker of xenobiotics, which are conjugated by glutathione? Arterioscler Thromb Vasc Biol. 2008;28(4):e26-8; author reply e29.
50. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006;55 Suppl 2:S9-15.
51. Dhanasekaran M, Ren J. The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus. Curr Neurovasc Res. 2005;2(5):447-59.
52. Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010;137(6):1410-6.
53. Taylor BS, Varambally S, Chinnaiyan AM. A systems approach to model metastatic progression. Cancer Res. 2006;66(11):5537-9.
54. Barrenas F, Chavali S, Holme P, Mobini R, Benson M. Network properties of complex human disease genes identified through genome-wide association studies. PLoS One. 2009;4(11):e8090.
55. Bosco A, McKenna KL, Firth MJ, Sly PD, Holt PG. A network modeling approach to analysis of the Th2 memory responses underlying human atopic disease. J Immunol. 2009;182(10):6011-21.
56. Chavali S, Barrenas F, Kanduri K, Benson M. Network properties of human disease genes with pleiotropic effects. BMC Syst Biol. 2010;4:78.
57. Dudley JT, Butte AJ. Identification of discriminating biomarkers for human disease using integrative network biology. Pac Symp Biocomput. 2009:27-38.
58. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. Proc Natl Acad Sci U S A. 2007;104(21):8685-90.
59. Jiang JQ, Dress AW, Chen M. Towards prediction and prioritization of disease genes by the modularity of human phenome-genome assembled network. J Integr Bioinform. 2010;7(2).
60. Lee DS, Park J, Kay KA, Christakis NA, Oltvai ZN, Barabasi AL. The implications of human metabolic network topology for disease comorbidity. Proc Natl Acad Sci U S A. 2008;105(29):9880-5.
61. Loscalzo J. Systems biology and personalized medicine: a network approachto human disease. Proc Am Thorac Soc. 2011;8(2):196-8.
62. Zanzoni A, Soler-Lopez M, Aloy P. A network medicine approach to human disease. FEBS Lett. 2009;583(11):1759-65.
63. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395-9.
64. Urbach D, Moore JH. Mining the diseasome. BioData Min. 2011;4:25.
65. Iakoubova OA, Robertson M, Tong CH, et al. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur J Cardiovasc Prev Rehabil. 2010;17(4):455-61.
66. Assimes TL, Holm H, Kathiresan S, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol. 2010;56(19):1552-63.
67. Mathew J, Narayanan P, Sundaram R, et al. Lack of association between Glu(298) asp polymorphism of endothelial nitric oxide synthase (eNOS) gene and coronary artery disease in Tamilian population. Indian Heart J. 2008;60(3):223-7.
68. Tsantes AE, Nikolopoulos GK, Bagos PG, Vaiopoulos G, Travlou A. Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: a meta-analysis. Int J Cardiol. 2007;118(2):189-96.
69. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res. 2005;116(6):491-7.
70. Schmoelzer I, Renner W, Paulweber B, et al. Lack of association of the Glu298Asp polymorphism of endothelial nitric oxide synthase with manifest coronary artery disease, carotid atherosclerosis and forearm vascular reactivity in two Austrian populations. Eur J Clin Invest. 2003;33(3):191-8.
71. Sigusch HH, Surber R, Lehmann MH, et al. Lack of association between 27-bp repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene and the risk of coronary artery disease. Scand J Clin Lab Invest. 2000;60(3):229-35.
72. Anderson JL, Muhlestein JB, Habashi J, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1999;34(6):1778-83.
73. Garg UC, Arnett DK, Folsom AR, Province MA, Williams RR, Eckfeldt JH. Lack of association between platelet glycoprotein IIb/IIIa receptor PlA polymorphism and coronary artery disease or carotid intima-media thickness. Thromb Res. 1998;89(2):85-9.
74. Fujimura T, Yokota M, Kato S, et al. Lack of association of angiotensin converting enzyme gene polymorphism or serum enzyme activity with coronary artery disease in Japanese subjects. Am J Hypertens. 1997;10(12 Pt 1):1384-90.
75. Halanych KM, Goertzen LR. Grand challenges in organismal biology: The need to develop both theory and resources. Integr Comp Biol. 2009;49(5):475-9.
76. Schwenk K, Padilla DK, Bakken GS, Full RJ. Grand challenges in organismal biology. Integr Comp Biol. 2009;49(1):7-14.
77. Lipton B. The biology of belief: unleashing the power of consciousness, matter, & miracles. 13 ed. New York: Hay House; 2011.
78. Duraffourd C, Lapraz JC. Traite de Phytotherapie Clinique: Medicine et Endobiogenie. Masson ed. Paris: Masson; 2002.
79. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160(9):1554-65.
80. Chiam K, Tilley WD, Butler LM, Bianco-Miotto T. The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers. Biochim Biophys Acta. 2009;1795(2):104-9.
81. Gerhard I, Waibel S, Daniel V, Runnebaum B. Impact of heavy metals on hormonal and immunological factors in women with repeated miscarriages. Hum Reprod Update. 1998;4(3):301-9.
82. Atkinson SA. Vitamin D status and bone biomarkers in childhood cancer. Pediatr Blood Cancer. 2008;50(2 Suppl):479-82; discussion 486.
83. Chlebna-Sokol D, Rusinska A. Serum insulin/like growth factor I, bone mineral density and biochemical markers of bone metabolism in children with idiopathic osteoporosis. Endocr Regul. 2001;35(4):201-8.
84. Delmas PD, Chatelain P, Malaval L, Bonne G. Serum bone GLA-protein in growth hormone deficient children. J Bone Miner Res. 1986;1(4):333-8.
85. Nimptsch K, Hailer S, Rohrmann S, Gedrich K, Wolfram G, Linseisen J. Determinants and correlates of serum undercarboxylated osteocalcin. Ann Nutr Metab. 2007;51(6):563-70.
86. Tarle M. Plasma osteocalcin values and related hormonal parameters in patients subjected to a variety of prostate anticancer agents. Urol Res. 1991;19(1):39-44.
87. Vietri MT, Sessa M, Pilla P, et al. Serum osteocalcin and parathyroid hormone in healthy children assessed with two new automated assays. J Pediatr Endocrinol Metab. 2006;19(12):1413-9.
88. Banu KS, Aruldhas MM. Sex steroids regulate TSH-induced thyroid growth during sexual maturation in Wistar rats. Exp Clin Endocrinol Diabetes. 2002;110(1):37-42.
89. Cuenca E, Serrano MI, Gibert-Rahola J, Galiana J. Enhancement of noradrenaline responses by thyrotropine-releasing hormone. J Pharm Pharmacol. 1975;27(3):199-200.
90. Gidron Y, Ronson A. Psychosocial factors, biological mediators, and cancer prognosis: a new look at an old story. Curr Opin Oncol. 2008;20(4):386-92.
91. Grimm Y, Reichlin S. Thyrotropin releasing hormone (TRH): neurotransmitter regulation of secretion by mouse hypothalamic tissue in vitro. Endocrinology. 1973;93(3):626-31.
92. Morley JE. Extrahypothalamic thyrotropin releasing hormone (TRH) - its distribution and its functions. Life Sci. Oct 29 1979;25(18):1539-1550.
93. Morley JE, Klein C, Kalk WJ, et al. Pituitary responsiveness to thyrotropin releasing hormone in insulin-dependent diabetes mellitus. Horm Metab Res. 1978;10(3):231-7.
94. Mortimer CH, Besser GM, McNeilly AS, Tunbridge WM, Gomez-Pan A, Hall R. Interaction between secretion of the gonadotrophins, prolactin, growth hormone, thyrotrophin and corticosteroids in man: the effects of LH FSHRH, TRH and hypoglycaemia alone and in combination. Clin Endocrinol (Oxf). Oct 1973;2(4):317-26.
95. Sekulic M, Sosic-Jurjevic B, Filipovic B, Manojlovic-Stojanoski M, Milosevic V. Immunoreactive TSH cells in juvenile and peripubertal rats after estradiol and human chorionic gonadotropin treatment. Acta Histochem. 2006;108(2):117-23.
96. Shah N, Evans WS, Veldhuis JD. Actions of estrogen on pulsatile, nyctohemeral, and entropic modes of growth hormone secretion. Am J Physiol. 1999;276(5 Pt 2):R1351-8.
97. Joosten KF, de Kleijn ED, Westerterp M, et al. Endocrine and metabolic responses in children with meningoccocal sepsis: striking differences between survivors and nonsurvivors. J Clin Endocrinol Metab. 2000;85(10):3746-53.
98. Goeters C, Mertes N, Tacke J, et al. Repeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Effect on metabolic and hormonal patterns. Ann Surg. 1995;222(5):646-53.
99. Radetti G, Paganini C, Gentili L, Barbin F, Pasquino B, Zachmann M. Altered adrenal and thyroid function in children with insulin-dependent diabetes mellitus. Acta Diabetol. 1994;31(3):138-40.
100. Bugaresti JM, Tator CH, Silverberg JD, et al. Changes in thyroid hormones, thyroid stimulating hormone and cortisol in acute spinal cord injury. Paraplegia. 1992;30(6):401-9.
101. Kjellman BF, Ljunggren JG, Beck-Friis J, Wetterberg L. Reverse T3 levels in affective disorders. Psychiatry Res. 1983;10(1):1-9.
102. Kahana L, Keidar S, Sheinfeld M, Palant A. Endogenous cortisol and thyroid hormone levels in patients with acute myocardial infarction. Clin Endocrinol (Oxf). 1983;19(1):131-9.
103. Koono N. Reciprocal changes in serum concentrations of triiodothyronine and reverse triiodothyronine between summer and winter in normal adult men. Endocrinol Jpn. 1980;27(4):471-6.
104. Banos C, Tako J, Salamon F, Gyorgyi S, Czikkely R. Effect of ACTHstimulated glucocorticoid hypersecretion on the serum concentrations of thyroxine-binding globulin, thyroxine, triiodothyronine, reverse triiodothyronine and on the TSH-response to TRH. Acta Med Acad Sci Hung. 1979;36(4):381-94.
105. Boomershine CS. A comprehensive evaluation of standardized assessment tools in the diagnosis of fibromyalgia and in the assessment of fibromyalgia severity. Pain Res Treat. 2011;2012:653714.
106. Simonsick EM, Newman AB, Ferrucci L, et al. Subclinical hypothyroidism and functional mobility in older adults. Arch Intern Med. 2009;169(21):2011-7.
107. Baek JH, Chung PW, Kim YB, et al. Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients. Endocr J. 2009;57(1):23-9.
108. Akcakoyun M, Kaya H, Kargin R, et al. Abnormal left ventricular longitudinal functional reserve assessed by exercise pulsed wave tissue Doppler imaging in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 2009;94(8):2979-83.
109. Sell MA, Schott M, Tharandt L, Cissewski K, Scherbaum WA, Willenberg HS. Functional central hypothyroidism in the elderly. Aging Clin Exp Res. 2008;20(3):207-10.
110. Tramoni E, Aubert-Khalfa S, Guye M, Ranjeva JP, Felician O, Ceccaldi M. Hypo-retrieval and hyper-suppression mechanisms in functional amnesia. Neuropsychologia. 2009;47(3):611-24.
111. Verslype C. Evaluation of abnormal liver-enzyme results in asymptomatic patients. Acta Clin Belg. 2004;59(5):285-9.
112. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. Apr 27 2000;342(17):1266-71.
113. Theal RM, Scott K. Evaluating asymptomatic patients with abnormal liver function test results. Am Fam Physician. 1996;53(6):2111-9.
114. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ. 1994;308(6943):1552.
115. Colglazier CL, Sutej PG. Laboratory testing in the rheumatic diseases: a practical review. South Med J. 2005;98(2):185-91.
116. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
117. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
118. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-62.
119. Cole M, Rutherford RB, Smith FO. Experimental ammonia encephalopathy in the primate. Trans Am Neurol Assoc. 1970;95:82-5.
120. Cole M, Rutherford RB, Smith FO. Experimental ammonia encephalopathy in the primate. Arch Neurol. 1972;26(2):130-6.
121. Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46(6):1844-52.
122. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57(8):1156-65.
123. Lee DH, Lim JS, Song K, Boo Y, Jacobs DR, Jr. Graded associations of blood lead and urinary cadmium concentrations with oxidative-stress-related markers in the U.S. population: results from the third National Health and Nutrition Examination Survey. Environ Health Perspect. 2006;114(3):350-4.
124. Shi M, Gozal E, Choy HA, Forman HJ. Extracellular glutathione and gammaglutamyl transpeptidase prevent H2O2-induced injury by 2,3-dimethoxy-1,4-naphthoquinone. Free Radic Biol Med. 1993;15(1):57-67.
125. Lee DH, Jacobs DR, Jr. Association between serum concentrations of persistent organic pollutants and gamma glutamyltransferase: results from the National Health and Examination Survey 1999-2002. Clin Chem. 2006;52(9):1825-7.
126. Lee DH, Steffes MW, Jacobs DR, Jr. Can persistent organic pollutants explain the association between serum gamma-glutamyltransferase and type 2 diabetes? Diabetologia. 2008;51(3):402-7.
127. Lee DH, Silventoinen K, Jacobs DR, Jr., Jousilahti P, Tuomileto J. gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab. 2004;89(11):5410-4.
128. Nemes Z, Devreese B, Steinert PM, Van Beeumen J, Fesus L. Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilonlysine bonds in Alzheimer's neurofibrillary tangles. FASEB J. 2004;18(10):1135-7.
129. Yates CM, Butterworth J, Gordon A. gamma-Glutamyl transpeptidase in dementia. Neurobiol Aging. 1989;10(1):107-8.
130. Butterworth J, Yates CM, Reynolds GP. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gammaglutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J Neurol Sci. 1985;67(2):161-71.
131. Loomba R, Rao F, Zhang L, et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology. 2010;139(3):836-45, 845 e831.
132. Bidel S, Silventoinen K, Hu G, Lee DH, Kaprio J, Tuomilehto J. Coffee consumption, serum gamma-glutamyltransferase and risk of type II diabetes. Eur J Clin Nutr. 2008;62(2):178-85.
133. Lee D, Jacobs Jr DR, Gross M, et al. Gamma-Glutamyltransferase is a predictor of incident diabetes and hypertension: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2003;49(8):1358-66.
134. Lee DH, Ha MH, Kim JH, et al. Gamma-glutamyltransferase and diabetes-a 4 year follow-up study. Diabetologia. Mar 2003;46(3):359-364.
135. Lee DH, Jacobs DR Jr, Gross M, Steffes M. Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. Jul 2005;51(7):1185-1191.
136. Lim JS, Lee DH, Park JY, Jin SH, Jacobs DR Jr. A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clin Chem. 2007;53(6):1092-1098.
137. Shin JY, Hwang JH, Jeong JY, et al. [The association of central obesity with type 2 diabetes among Koreans according to the serum gamma-glutamyltransferase level: Korean genome and epidemiology study]. J Prev Med Public Health. Nov 2009;42(6):386-391.
138. Song SH, Kwak IS, Kim YJ, et al. Can gamma-glutamyltransferase be an additional marker of arterial stiffness? Circ J. Nov 2007;71(11):1715-20.
139. Targher G, Zoppini G, Lippi G, Guidi GC, Muggeo M. Effect of serum gamma-glutamyltransferase and obesity on the risk of dyslipidemia and poor glycemic control in type 2 diabetic patients: cross-sectional findings from the Verona Diabetes Study. Clin Chem. 2007;53(10):1867-69; author reply 1869-70.
140. Kawamoto R, Kohara K, Tabara Y, Miki T, Otsuka N. Serum gamma-glutamyl transferase levels are associated with metabolic syndrome in communitydwelling individuals. J Atheroscler Thromb. 2009;16(4):355-62.
141. Hwang JH, Shin JY, Chun B, et al. Association between gamma-glutamyltransferase and hypertension incidence in rural prehypertensive adults. J Prev Med Public Health. 2010;43(1):18-25. [Korean.]
142. Lee DH, Ha MH, Kim JR, Gross M, Jacobs DR Jr. Gamma-glutamyltransferase, alcohol, and blood pressure. A four-year follow-up study. Ann Epidemiol. 2002;12(2):90-6.
143. Lee DH, Ha MH, Kim KY, Jin DG, Jacobs DR Jr. Gamma-glutamyltransferase: an effect modifier in the association between age and hypertension in a 4-year follow-up study. J Hum Hypertens. 2004;18(11):803-7.
144. Kotani K, Shimohiro H, Adachi S, Sakane N. The association between an increased level of gamma-glutamyl transferase and systolic blood pressure in diabetic subjects. Tohoku J Exp Med. 2008;214(4):321-5.
145. Kotani K, Shimohiro H, Adachi S, Sakane N. Changes in serum gamma-glutamyl transferase and blood pressure levels in subjects with normal blood pressure and prehypertension. Clin Chim Acta. 2008;389(1-2):189-90.
146. Yamada Y, Ikai E, Tsuritani I, Ishizaki M, Honda R, Ishida M. The relationship between serum gamma-glutamyl transpeptidase levels and hypertension: common in drinkers and nondrinkers. Hypertens Res. 1995;18(4):295-301.
147. Miura K, Nakagawa H, Nakamura H, et al. Serum gamma-glutamyl transferase level in predicting hypertension among male drinkers. J Hum Hypertens. 1994;8(6):445-9.
148. Ikai E, Noborizaka Y, Tsuritani I, Honda R, Ishizaki M, Yamada Y. Serum gamma-glutamyl transpeptidase levels and hypertension in non-drinkers: a possible role of fatty liver in the pathogenesis of obesity related hypertension. Obes Res. 1993;1(6):469-74.
149. Yamada Y, Ishizaki M, Kido T, et al. Alcohol, high blood pressure, and serum gamma-glutamyl transpeptidase level. Hypertension. 1991;18(6):819-26.
150. Yamada Y, Ishizaki M, Kido T, Honda R, Tsuritani I, Yamaya H. Relationship between serum gamma-glutamyl transpeptidase activity and blood pressure in middle-aged male and female non-drinkers. J Hum Hypertens. 1990;4(6):609-614.
151. Henningsen NC, Ohlsson O, Mattiasson I, Trell E, Kristensson H, Hood B. Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Med Scand. 1980;207(4):245-51.
152. Ablin RJ. Prostate-specific antigen: chronology of its identification. Oncology (Williston Park). 1998;12(7):1016.
153. Ablin RJ. A retrospective and prospective overview of prostate-specific antigen. J Cancer Res Clin Oncol. 1997;123(11-12):583-94.
154. Gupta S, Camm AJ. Chlamydia pneumoniae and coronary heart disease. BMJ. 1997;314(7097):1778-9.
155. Otto SJ, Moss SM, Maattanen L, et al. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer. 2010;46(17):3053-60.
156. Gura T. Chlamydia protein linked to heart disease. Science. 1999;283(5406):1238-9.
157. Mendall MA, Carrington D, Strachan D, et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect. 1995;30(2):121-8.
158. Miettinen H, Lehto S, Saikku P, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J. 1996;17(5):682-8.
159. Miyashita N, Toyota E, Sawayama T, Matsushima T. An association of an antibody against Chlamydia pneumoniae and coronary heart disease observed in Japan. Eur Heart J. 1998;19(6):971.
160. Naidu BR, Ngeow YF, Kannan P, et al. Evidence of Chlamydia pneumoniae infection obtained by the polymerase chain reaction (PCR) in patients with acute myocardial infarction and coronary heart disease. J Infect. 1997;35(2):199-200.
161. Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang SP, Chambless LE. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 1999;150(2):149-56.
162. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2(8618):983-6.
163. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116(4):273-8.
164. Taylor-Robinson D, Thomas BJ. Antibodies to cytomegalovirus or Chlamydia pneumoniae and coronary heart disease. Lancet. 1998;351(9096):142; author reply 143.
165. Quinn TC. Does Chlamydia pneumoniae cause coronary heart disease? Curr Opin Infect Dis. 1998;11(3):301-7.
166. Song Z, Brassard P, Brophy JM. A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases. Can J Cardiol. 2008;24(5):391-5.
167. Stassen FR, Vainas T, Bruggeman CA. Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol Rep. 2008;60(1):85-92.
168. Jafarzadeh A, Esmaeeli-Nadimi A, Shariati M. High sensitivity C-reactive protein and immunoglobulin G against Chlamydia pneumoniae and chlamydial heat shock protein-60 in ischemic heart disease. Iran J Immunol. 2008;5(1):51-6.
169. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963-8.
170. Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci. 2009;338(1):40-4.
171. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):50311.
172. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754-9.
173. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996;24(5):743-52.
174. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med. May 2006;34(5):1297-1310.
175. Chen BS, Wang YC, Wu WS, Li WH. A new measure of the robustness of biochemical networks. Bioinformatics. 2005;21(11):2698-705.
176. Hwang D, Rust AG, Ramsey S, et al. A data integration methodology for systems biology. Proc Natl Acad Sci U S A. 2005;102(48):17296-301.
177. Hwang D, Smith JJ, Leslie DM, et al. A data integration methodology for systems biology: experimental verification. Proc Natl Acad Sci U S A. 2005;102(48):17302-17307.
178. Bain BJ, England JM. Normal haematological values: sex difference in neutrophil count. Br Med J. 1975;1(5953):306-9.
179. Molloy EJ, O'Neill AJ, Grantham JJ, et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood. 2003;102(7):2653-9.
180. Bain B, Seed M, Godsland I. Normal values for peripheral blood white cell counts in women of four different ethnic origins. J Clin Pathol. 1984;37(2):188-93.
181. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol. 1996;49(8):664-6.
182. Chan PC, Hayes L, Bain BJ. A comparison of the white cell counts of cord blood from babies of different ethnic origins. Ann Trop Paediatr. 1985;5(3):153-5.
183. Daughaday WH, Williams RH, Daland GA. The effect of endocrinopathies on the blood. Blood. 1948;3(12):1342-66.
184. Carryer HM, Berkman JM, Mason HL. Relative lymphocytosis in anorexia nervosa. Proc Staff Meet Mayo Clin. 1959;34:426-32.
185. Le Marquand HS, Tozer FH. Fragilitas ossium in a family showing both thickening and rarefaction of bones, relative lymphocytosis and raised serum phosphatase with absence of blue sclerotics and otosclerosis. Proc R Soc Med. 1935;28(12):1640-1.
186. Menkin V. Relative lymphocytosis in hyperthyroidism. Arch Intern Med. 1928;42:419-24.
187. Gardner FH, Pringle JC, Jr. Androgens and erythropoiesis. I. Preliminary clinical observations. Arch Intern Med. 1961;107:846-62.
188. Naets JP, Wittek M. The mechanism of action of androgens on erythropoiesis. Minerva Nucl. 1965;9(5):281-4.
189. Gardner FH, Nathan DG. Androgens and erythropoiesis. 3. Further evaluation of testosterone treatment of myelofibrosis. N Engl J Med. 1966;274(8):420-6.
190. Naets JP, Wittek M. Mechanism of action of androgens on erythropoiesis. Am J Physiol. 1966;210(2):315-20.
191. Fisher JW, Samuels AI, Malgor LA. Androgens and erythropoiesis. Isr J Med Sci. 1971;7(7):892-900.
192. Gardner FH, Gorshein D. Regulation of erythropoiesis by androgens. Trans Am Clin Climatol Assoc. 1973;84:60-70.
193. Evens RP, Amerson AB. Androgens and erythropoiesis. J Clin Pharmacol. 1974;14(2):94-101.
194. Cruickshank JM, Morris R, Butt WR, Crooke AC. The relationship of total and differential leukocyte counts with urinary oestrogen and plasma cortisol levels. J Obstet Gynaecol Br Commonw. 1970;77(7):634-9.
195. Cruickshank JM, Morris R, Butt WR, Corker CS. Inter-relationships between levels of plasma oestradiol, urinary total oestrogens and blood haemoglobin and neutrophil counts. J Obstet Gynaecol Br Commonw. 1972;79(5):450-4.
196. Riedel-Baima B, Riedel A. Female pattern hair loss may be triggered by low oestrogen to androgen ratio. Endocr Regul. 2008;42(1):13-6.
197. Chang RJ, Katz SE. Diagnosis of polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999;28(2):397-408.
198. Goudas VT, Dumesic DA. Polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1997;26(4):893-912.
199. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol. 2002;167(2 Pt 1):624-9.
200. Fejes I, Koloszar S, Zavaczki Z, Daru J, Szollosi J, Pal A. Effect of body weight on testosterone/estradiol ratio in oligozoospermic patients. Arch Androl. 2006;52(2):97-102.
201. Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol. 2001;153(1):1-10.
202. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93(7):1354-63.
203. Shimomura K, Manda T, Mukumoto S, Kobayashi K, Nakano K, Mori J. Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity. Int J Cancer. 1988;41(2):243-7.
204. Yacoub D, Hachem A, Theoret JF, Gillis MA, Mourad W, Merhi Y. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol. 2010;30(12):2424-33.
205. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine (Phila, Pa 1976). 2001;26(8):863-9.
206. Ohtsu H. Progress in allergy signal research on mast cells: the role of histamine in immunological and cardiovascular disease and the transporting system of histamine in the cell. J Pharmacol Sci. 2008;106(3):347-53.
207. Ozben B, Erdogan O. The role of inflammation and allergy in acute coronary syndromes. Inflamm Allergy Drug Targets. Sep 2008;7(3):136-144.
208. Tanimoto A, Sasaguri Y, Ohtsu H. Histamine network in atherosclerosis. Trends Cardiovasc Med. 2006;16(8):280-4.
209. D'Ascenzo S, Millimaggi D, Di Massimo C, et al. Detrimental effects of anabolic steroids on human endothelial cells. Toxicol Lett. 2007;169(2):129-36.
210. Dickerman RD, McConathy WJ, Zachariah NY. Testosterone, sex hormonebinding globulin, lipoproteins, and vascular disease risk. J Cardiovasc Risk. 1997;4(5-6):363-6.
211. Dickerman RD, McConathy WJ, Schaller F, Zachariah NY. Cardiovascular complications and anabolic steroids. Eur Heart J. Dec 1996;17(12):1912.
212. Winkler UH. Effects of androgens on haemostasis. Maturitas. Jul 1996;24(3):147-55.
213. Halushka PV, Masuda A, Matsuda K. The Gordon Wilson Lecture. Regulation of thromboxane A2 receptors by testosterone: implications for steroid abuse and cardiovascular disease. Trans Am Clin Climatol Assoc. 1994;105:95-103.
214. Noh JY, Lim KM, Bae ON, et al. Procoagulant and prothrombotic activation of human erythrocytes by phosphatidic acid. Am J Physiol Heart Circ Physiol. 2010;299(2):H347-55.
215. Santos MT, Valles J, Lago A, et al. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost. 2008;6(4):615-21.
216. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation. 1998;97(4):350-5.
217. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation. 1997;95(1):63-8.